DOI · e01.org

When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer

Hong-Sik Kim, Hana Kim, Min‐Sang Lee, Minsuk Kwon, Jung Yong Hong, Jeeyun Lee, Ho Yeong Lim, Won Ki Kang, Seung Tae Kim · Journal of Cancer · 2021

  • DOI 10.7150/jca.62853
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2021

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2021

Abstract

Background: Immune checkpoint inhibitors (ICIs) show clinical benefit in patients with refractory advanced gastric cancer (GC).The ICIs in routine clinical practice have been used in various treatment lines.Therefore, we investigated the timing for application of ICI in patients with refractory advanced GC.

Methods: We analyzed 187 patients with refractory advanced or recurrent GC who received ICIS as a 3rd-or 4th-line treatment between September 2015 and October 2020.Clinical outcomes of overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were evaluated.Results: Among 187 patients, 105 received ICIs as a 3rd-line treatment and 82 as a 4th line.The ORR for ICIs was 10.5% (11/105) in 3rd line and 8.5% (7/82) in 4th line.The DCR for ICIs was 36.2% (38/105) in 3rd-line treatment and 31.7%(26/82) in 4th line.There was no significant difference for ORR (P = 0.819) or DCR (P = 0.870).The median PFS and OS to ICIs was 1.4 months (95% CI, 1.1 to 1.8 months) and 4.4 months (95% CI, 1.6 to 7.2 months) in 3rd line and 1.8 months (95% CI, 1.4 to 2.3 months) and 2.8 months (95% CI, 2.2 to 3.4 months) in 4th line.The median PFS and OS to ICIs was not different between 3rd line and 4th line (P = 0.495 and P=0.208, respectively).There were also no significant difference for PFS and OS between PD-L1-positive tumors (CPS≥1) and PD-L1-negative tumors (P = 0.910 and P=0.931, respectively).Conclusions: ICIs showed similar clinical benefits in the 3rd-line and 4th-line settings.ICIs might be a reasonable approach for patients with refractory GC in the setting of 3rd-line or 4th-line treatment options.

Open the resolved locator · 10.7150/jca.62853

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:21 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v12p5681.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.